Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.82 USD

44.82
11,316,753

-1.03 (-2.25%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $44.83 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

by Zacks Equity Research

AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.

    Zacks Equity Research

    Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

    by Zacks Equity Research

    Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

      Zacks Equity Research

      What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

      by Zacks Equity Research

      Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

        Sweta Killa headshot

        Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

        by Sweta Killa

        Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

          Zacks Equity Research

          What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

          by Zacks Equity Research

          Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

            Arpita Dutt headshot

            Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

            by Arpita Dutt

            Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

              Zacks Equity Research

              Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

              by Zacks Equity Research

              Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

                Zacks Equity Research

                Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                by Zacks Equity Research

                Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                  Zacks Equity Research

                  Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                  by Zacks Equity Research

                  Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                    Zacks Equity Research

                    Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

                    by Zacks Equity Research

                    Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                      Arpita Dutt headshot

                      Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

                      by Arpita Dutt

                      3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

                        Zacks Equity Research

                        Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study

                        by Zacks Equity Research

                        Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.

                          Zacks Equity Research

                          Company News for July 06, 2017

                          by Zacks Equity Research

                          Companies in the News are: ORLY,BMY,MORE,PRPO

                            Zacks Equity Research

                            Gilead's (GILD) HCV Drug Application Accepted in the EU

                            by Zacks Equity Research

                            Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                              Zacks Equity Research

                              Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                              by Zacks Equity Research

                              Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                                Zacks Equity Research

                                AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

                                by Zacks Equity Research

                                AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

                                  by Arpita Dutt

                                  All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

                                    Zacks Equity Research

                                    AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

                                    by Zacks Equity Research

                                    AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

                                      Zacks Equity Research

                                      Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                                      by Zacks Equity Research

                                      Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                                        Zacks Equity Research

                                        Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

                                        by Zacks Equity Research

                                        Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

                                          Zacks Equity Research

                                          Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205

                                          by Zacks Equity Research

                                          Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

                                            Zacks Equity Research

                                            J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                                            by Zacks Equity Research

                                            Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

                                              by Arpita Dutt

                                              Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

                                                Zacks Equity Research

                                                Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                                                by Zacks Equity Research

                                                Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                                                  Zacks Equity Research

                                                  Novartis, Bristol-Myers Collaborate for Opdivo Combination

                                                  by Zacks Equity Research

                                                  Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.